Thomas W. Dubensky
- Immunology top 0.2%
- Immunotherapy and Immune Responses 32
- interferon and immune responses 18
- Immune Response and Inflammation 9
- Infectious Diseases top 0.5%
- Biotechnology top 0.5%
- Cancer Research and Treatments 17
- Listeria monocytogenes in Food Safety 10
- Oncology top 1%
- Virology top 2%
-
- Virus-based gene therapy research 23
-
- RNA Interference and Gene Delivery 10
- vaccines and immunoinformatics approaches 9
- Co-authors
- Sarah M. McWhirterLeticia CorralesDavid B. KanneThomas F. GajewskiDirk G. BrockstedtEdward E. LemmensKelsey E. SivickMeredith L. Leong
- Journals
- Proceedings of the National Academy of Sciences (5 papers)Journal of Clinical Investigation (3 papers)Nature Medicine (3 papers)
- Partner nations
- United StatesJapanFrance
In The Last Decade
Thomas W. Dubensky
99 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Immunology 4.8k
- Infectious Diseases 1.8k
- Biotechnology 771
- Oncology 2.1k
- Virology 239
Countries citing papers authored by Thomas W. Dubensky
This map shows the geographic impact of Thomas W. Dubensky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. Dubensky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. Dubensky more than expected).
Fields of papers citing papers by Thomas W. Dubensky
This network shows the impact of papers produced by Thomas W. Dubensky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. Dubensky. The network helps show where Thomas W. Dubensky may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas W. Dubensky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 11 | |
| 2 | 2023 | 20 | |
| 3 | Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomasbreakdown → | 2021 | 240 |
| 4 | 2018 | 67 | |
| 5 | 2018 | 132 | |
| 6 | 2018 | 91 | |
| 7 | 2017 | 39 | |
| 8 | 2017 | 117 | |
| 9 | 2015 | 201 | |
| 10 | 2015 | 54 | |
| 11 | 2008 | 86 | |
| 12 | 2007 | 21 | |
| 13 | 2006 | 48 | |
| 14 | 2006 | 318 | |
| 15 | 2004 | 74 | |
| 16 | 2002 | 38 | |
| 17 | 2002 | 232 | |
| 18 | 2002 | 15 | |
| 19 | 2001 | 9 | |
| 20 | 1999 | 134 |
About Thomas W. Dubensky
Thomas W. Dubensky is a scholar working on Biotechnology, Immunology and Infectious Diseases, having authored 99 papers that have together received 7.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (32 papers), Virus-based gene therapy research (23 papers), interferon and immune responses (18 papers), Cancer Research and Treatments (17 papers), RNA Interference and Gene Delivery (10 papers), Listeria monocytogenes in Food Safety (10 papers), vaccines and immunoinformatics approaches (9 papers) and Immune Response and Inflammation (9 papers). The work is most often cited by research in Immunology (4.8k citations), Infectious Diseases (1.8k citations) and Biotechnology (771 citations). Thomas W. Dubensky has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Sarah M. McWhirter, Leticia Corrales, David B. Kanne, Thomas F. Gajewski, Dirk G. Brockstedt, Edward E. Lemmens, Kelsey E. Sivick, Meredith L. Leong, Laura Hix Glickman and Justin J. Leong. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.